MedPath

Effect of Vitamin D on Management of Attention Deficit Hyperactivity Disorder

Phase 3
Recruiting
Conditions
Attention Deficit Hyperactivity Disorder.
Attention-deficit hyperactivity disorders
Registration Number
IRCT20161104030698N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
84
Inclusion Criteria

1- In the age group of 13-6 years
2- Attention deficit hyperactivity disorder has been diagnosed and taken appropriate medications by the child and adolescent psychiatrist
3- Both groups take the same drugs at the same dose. Due to various psychiatric problems in this disorder and the ethical abnormal use of Ritalin, patients in the two groups take other drugs other than Ritalin according to the needs of the psychiatrist, but the range of medications used in the two groups is the same
4- Resident in Isfahan city

Exclusion Criteria

1. Use of any non-pharmaceutical treatment
2. Use of vitamin D and multivitamins supplement, foods rich in vitamin D or any supplementation of vitamin D received three months before the start of the study
3. Patients with other chronic diseases except for ?attention deficit hyperactivity disorder

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
25-hydroxy Vitamin D3. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of C-reactive protein. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of interleukin-6. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of homocysteine. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum levels of superoxide dismutase. Timepoint: At the beginning of the study and after 12 weeks of the intervention. Method of measurement: Spectrophotometric method.
Secondary Outcome Measures
NameTimeMethod
Food intake. Timepoint: At the beginning of the study. Method of measurement: Food Frequency Questionnaire.;Sunlight exposure. Timepoint: At the beginning of the study. Method of measurement: Questionnaire.;Physical activity. Timepoint: At the beginning of the study. Method of measurement: Baecke Physical Activity Questionnaire.
© Copyright 2025. All Rights Reserved by MedPath